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Chemotherapy is used to treat numerous cancers including melanoma. However, its effectiveness in clinical settings is often
hampered by various mechanisms. Previous studies have demonstrated that prooxidative stressor-mediated generation of oxidized
lipids with platelet-activating factor-receptor (PAF-R) agonistic activity induces systemic immunosuppression that augments the
growth of experimental melanoma tumors. We have recently shown that treatment of murine B16F10 melanoma cells in vitro or
tumors implanted into syngeneic mice and treated intratumorally with various chemotherapeutic agents generated PAF-R agonists
in a process blocked by antioxidants. Notably, these intratumoral chemotherapy-generated PAF-R agonists augmented the growth
of secondary (untreated) tumors in a PAF-R dependent manner. As both localized and systemic chemotherapies are used based
on tumor localization/stage and metastases, the current studies were sought to determine effects of PAF-R agonists on systemic
chemotherapy against experimental melanoma. Here, we show that systemic chemotherapy with etoposide (ETOP) attenuates the
growth of melanoma tumors when given subsequent to the tumor cell implantation. Importantly, this ETOP-mediated suppression
ofmelanoma tumor growthwas blocked by exogenous administration of a PAF-R agonist, CPAF.These findings indicate that PAF-R
agonists not only negatively affect the ability of localized chemotherapy but also compromise the efficacy of systemic chemotherapy
against murine melanoma.
1. Introduction
Despite all available treatment options, the annual mortality
rate of malignant melanoma is rapidly increasing in the
United States [1, 2]. Although new immune based approaches
such as anticytotoxic T lymphocyte antigen 4 (anti-CTLA-4)
and antiprogrammed death 1 (anti-PD-1) have shown consid-
erable promise in a subset of melanoma patients, systemic
chemotherapy is still considered an option for advanced
melanoma [3–5]. Several cellular resistancemechanisms exist
that affect the clinical efficacy of chemotherapy against
solid tumors including melanoma [6–9]. Of significance,
chemotherapeutic agents due to their ability to induce the
generation of reactive oxygen species (ROS) act as potent
prooxidative stressors [10–12].
Several studies including ours have shown that proox-
idative stressors, like ultraviolet B (UVB), generate the potent
lipid mediator platelet-activating factor (PAF) and novel
oxidized lipid glycerophosphocholines (Ox-GPCs)with PAF-
R agonistic (or PAF-like) activity directly from cellular
membrane phospholipids [13–17]. PAF and Ox-GPCs medi-
ate their effects via binding to a seven-transmembrane-
G-protein coupled receptor, the PAF-receptor (PAF-R),
expressed on various immune and nonimmune cell types
and cancer cells including melanoma [18–20]. PAF-R ago-
nists/Ox-GPCs mediate systemic immunosuppression via
cyclooxygenase type 2 (COX-2) dependent induction of the
immunosuppressive cell type, regulatory T cells (Tregs), and
the cytokine interleukin-10 (IL-10) [17, 21–24]. Importantly,
our studies have shown that this PAF-R agonists-mediated
Hindawi Publishing Corporation
Mediators of Inﬂammation
Volume 2015, Article ID 820543, 6 pages
http://dx.doi.org/10.1155/2015/820543
2 Mediators of Inflammation
systemic immunosuppression augments the growth of exper-
imental cancers including melanoma and lung carcinoma in
a PAF-R dependent fashion [25, 26].
Among various notable pathophysiological functions
including cancer growth, angiogenesis, and metastases, PAF
has been reported to modulate the effectiveness of chemo-
therapeutic agents [27, 28]. Importantly, our recent studies
have provided compelling evidence that chemotherapeutic
agents such as melphalan, etoposide (ETOP), dacarbazine,
and cisplatin generate PAF-R agonists from PAF-R deficient
murine B16F10 melanoma cells in a time and dose dependent
manner and that this effect was pronounced in B16F10 cells
expressing the PAF-R [29]. In a dual tumormodel, where two
melanoma tumors were implanted into syngeneic mice and
only one tumor was treated intratumorally with chemother-
apeutic agents (melphalan or ETOP) either in syngeneic
mice expressing or deficient in the PAF-R, we demonstrated
that chemotherapy-generated PAF-R agonists augmented the
growth of secondary tumors in a PAF-R dependent manner
[29]. Notably, this effect was blocked by systemic adminis-
tration of antioxidants, COX-2 inhibitors, and neutralizing
antibodies against Tregs, indicating an importance of the
PAF/PAF-R signaling in potentially offsetting the therapeutic
efficacy of intratumoral (localized) chemotherapy against
murine melanoma [29]. In addition, perfusates collected
from patients undergoing isolated limb chemoperfusion with
melphalan chemotherapy for melanoma tumors residing in
extremities exhibited high levels of PAF-R agonists, indicat-
ing that chemotherapeutic agents generate PAF-R agonists in
human subjects [29].
Of significance, both localized and systemic chemother-
apy are explored for melanoma patients based on the tumor
localization, its stage, and metastases [4, 5, 30–32]. Given
the findings of our study that PAF-R agonists can modulate
an efficacy of intratumoral chemotherapy for experimen-
tal melanoma, its role in systemic chemotherapy needs to
be elucidated. Our current studies demonstrate that sys-
temic chemotherapy suppresses the growth of experimental
melanoma tumors when started subsequent to the tumor cell
implantation and that this effect is blocked by administration
of the PAF-R agonist, carbamoyl-PAF (CPAF). These studies
suggest that exogenous PAF-R agonists can subvert systemic
chemotherapy.
2. Materials and Methods
2.1. Reagents and Cell Lines. All chemicals were obtained
from Sigma-Aldrich unless indicated otherwise. Murine
melanoma B16F10 and lymphoma EL4 cells were procured
from ATCC and grown in DMEM high glucose media
supplemented with 10% fetal calf serum and 100 𝜇g/mL
mixture of penicillin and streptomycin.
2.2. Mice. Female C57BL/6-wild-type mice (PAF-R express-
ing; age 7-8 weeks) were purchased from the Charles River
Laboratories. All mice were housed under specific pathogen-
free conditions. All procedures were approved by the Institu-
tional Animal Care andUse Committee of IndianaUniversity
School of Medicine.
2.3. In Vivo Tumor Growth Studies. To determine effects
of systemic ETOP chemotherapy against experimental
melanoma, 0.5 × 106 murine B16F10 cells, which lack the
functional PAF-R [25], were implanted subcutaneously (s.c.)
into the shaved right hind flanks of syngeneic C57BL/6 (WT)
mice. ETOP treatment at the dose of 36mg/kg (dissolved in
100 𝜇L PBS with 0.5% DMSO) was started intraperitoneally
(i.p.) either on day 6, day 3, or day 0 following tumor
cell implantation and repeated every 3 days afterwards.
Control mice received 0.5% DMSO in 100 𝜇L PBS i.p. as
vehicle. The working dose of ETOP (36mg/kg) was selected
from our recently published studies [29]. To determine
the effect of systemic PAF-R agonists on ETOP-mediated
modulation of experimental melanoma tumor growth,
WT mice were implanted with 0.5 × 106 B16F10 cells s.c.
followed by i.p. treatments with or without ETOP and
PAF-R agonist, CPAF (nonmetabolizable carbamoyl-PAF)
at a dose of 250 ng/mouse at days 0, 6, and 12 as per our
published protocols [25]. Tumor growth (major and minor
circumferences) was monitored and measured every 3 days
before treatments with digital calipers (Mitutoyo Corp.,
Aurora, IL), and tumor volume was calculated (major
circumference ×minor circumference2/2). To assess whether
systemic PAF-R agonists modulate tumor growth other than
B16F10, 0.5 × 106 murine EL4 lymphoma tumor cells were
implanted s.c. into WT mice followed by i.p. injections of
CPAF and measurement of tumor growth as described.
2.4. Statistical Analysis. All murine studies utilized at least
four mice per experimental group and repeated as necessary
to verify reproducibility and provide additional data for
analysis. All statistical calculations were performed using
GraphPad Prism 5. We used Student’s t-tests for comparing
two groups and one-way ANOVA with post hoc Bonferroni
tests for more than two groups. The data represent mean
values with SEM. Differences were considered statistically
significant when the 𝑃 value was less than 0.05.
3. Results and Discussion
Our recently published studies have demonstrated that
chemotherapeutic agents generate PAF-R agonists from
experimental murine B16F10 cells in vitro and in vivo
[29]. Importantly, intratumoral (localized) chemotherapy-
generated PAF-R agonists augmented the growth of preex-
isting secondary (untreated) melanoma tumors in a PAF-
R dependent fashion [29]. Notably, these studies used a
dual tumor model (two tumors were implanted but only
one tumor was treated and the other tumor left untreated)
to directly assess the ability of intratumoral chemotherapy
mediated PAF-R agonists generation in the modulation of
experimental melanoma tumor growth. As cancer patients
can be subjected to numerous types of PAF-R agonists
generating prooxidative stressors such as cigarette smoke
and UVB radiation, the current studies were designed to
test whether exogenous PAF-R agonists can modulate sys-
temic chemotherapy. Although a combination of systemic
chemotherapy and PAF-R antagonist has been shown to be
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Figure 1: Modulation of B16F10 tumor growth by systemic chemotherapy with etoposide (ETOP) and the effect of PAF-R agonist (CPAF).
(a) Murine B16F10 melanoma tumor cells (0.5 × 106) were implanted into the shaved dorsal hind flanks of syngeneic C57BL/6-WTmice (5–7
mice/group) subcutaneously (day 0). Mice were treated with or without ETOP (36mg/kg) intraperitoneally either at day 0, day 3, or day 6
repeated at every 3 days until the end of the experiment. Control mice received the vehicle (0.5% DMSO in 100 𝜇L PBS) by the same route.
Tumor growth was monitored and measured with digital caliper and tumor volume (major circumference × minor circumference2/2) was
expressed asmean ± SEMper group. Statistical differences (∗∗𝑃 > 0.01) were noted between vehicle and ETOP treatment (day 0) at day 15. (b)
Following subcutaneous B16F10 tumor cell implantation, C57BL/6-WTmice were treated with or without ETOP (36mg/kg) intraperitoneally
at day 0 repeated every 3 days until the end of the experiment. CPAF treatment (250 ng/mouse) was given intraperitoneally at days 0, 6, and
12. Control mice received the vehicle (0.5% DMSO in 100 𝜇L PBS) by the same route. Tumor growth was measured and tumor volume (major
circumference ×minor circumference2/2) was expressed as mean ± SEM per group and compared between the groups. Statistical differences
were noted between (1) ∗∗𝑃 < 0.01, vehicle and ETOP groups; (2) ∗𝑃 < 0.05, vehicle and CPAF groups; and (3) ∗∗∗𝑃 < 0.001, ETOP and
CPAF and ETOP and ETOP + CPAF groups at day 15.
effective in suppressing the growth of human melanoma
tumors implanted in immune compromised nude mice [28],
the role of PAF-R agonists in the modulation of systemic
chemotherapy has not been studied.
The first studies were designed to test if systemic chem-
otherapy with ETOP can attenuate experimental melanoma
tumor growth in settings when ETOP treatments are given
either subsequent to tumor cell implantation (day 0), after 3
days, or at day 6 (when more than half of the mice developed
palpable tumors). To that end, PAF-R expressing C57BL/6-
WT mice were implanted with PAF-R deficient murine
B16F10 melanoma tumor cells followed by treatments with
or without ETOP at day 0, day 3, or day 6 intraperitoneally
repeated at every alternate 3 days until the end of the
experiment. Our studies demonstrate that ETOP failed to
suppress the growth ofmelanoma tumors when started at day
3 (Figure 1(a)) or day 6 (data not shown) as the differences
in tumor volumes in ETOP versus vehicle-treated groups
were not statistically significant. However, we observed a
significant difference in the suppression of B16F10 tumor
xenografts by ETOP treatment started at day 0 (Figure 1(b)).
These studies are consistent with de Oliveira et al. studies
demonstrating that dacarbazine only modestly suppressed
the growth of B16F10 xenografts in C57BL/6 mice when
started after 3 days of tumor cell implantation [28].
Our previous studies have shown that PAF-R agonists
produced via various prooxidative stressors mediate systemic
immunosuppression [17, 21–24, 33]. This systemic immuno-
suppression results in an augmentation of experimental
melanoma tumor growth in a PAF-R dependent fashion in
a process blocked by antioxidants, inhibitors of COX-2, or
Tregs [25]. Notably, administration of PAF-R agonist, CPAF,
mimicked prooxidative stressor-generated PAF-R agonist
mediated effects [25]. Our next studies investigated if CPAF
can modulate ETOP effectiveness in preclinical settings that
resulted in significant suppression of experimentalmelanoma
tumor growth (Figure 1(b)). To accomplish this, WT mice
were implanted with B16F10 tumor cells followed by treat-
ment with or without ETOP and CPAF as described by us
previously [25]. We observed that CPAF-alone treated mice
(used as a positive control) exhibited enhanced tumor growth
compared to vehicle-treated mice (Figure 1(b)). Interestingly,
a group of mice treated with both ETOP and CPAF resulted
in augmentation of melanoma tumor growth similarly as
seen in CPAF-alone treated group compared to ETOP and
vehicle alone treated groups (Figure 1(b)). Notably, we did not
observe any significant differences in murine weights with or
without treatments in these studies (data not shown). These
findings indicate that PAF-R agonists block ETOP effective-
ness against murine melanoma. These studies are consistent
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Figure 2: Effect of CPAF on EL4 tumor growth and comparison of basal B16F10 and EL4 tumor growth. (a) Murine syngeneic EL4
lymphoma tumor cells (0.5 × 106) were implanted subcutaneously into the shaved dorsal hind flanks of C57BL/6WTmice (4-5 mice/group).
CPAF treatment (250 ng/mouse) was given intraperitoneally at days 0, 6, and 12. Tumor growth was measured and tumor volumes (major
circumference × minor circumference2/2) were compared between the groups. (b) The basal growth rates between B16F10 and EL4 tumors
were compared by assessing tumor volumes (major circumference ×minor circumference2/2). Statistical differences were noted between EL4
and B16F10 tumors at day 6 (∗∗∗𝑃 < 0.001), day 9 (∗∗∗𝑃 < 0.001), day 12 (∗∗∗𝑃 < 0.001), and day 15 (∗∗𝑃 < 0.01).
with our recent studies assessing the role of intratumoral
chemotherapy-generated PAF-R agonists in the modulation
of B16F10 tumor growth using a dual tumor model [29].
We demonstrated that PAF-R agonists generated via intra-
tumoral melphalan or ETOP chemotherapy by one tumor
augmented the growth of second (untreated) tumor in a PAF-
R dependentmanner, indicating the importance of PAF/PAF-
R signaling in attenuating the therapeutic efficacy of classical
chemotherapeutic agents against murine melanoma [29].
These findings are in agreement with de Oliveira et al.
studies demonstrating that systemic administration of PAF-R
antagonist, WEB2170, significantly suppressed the growth of
B16F10 tumors inC57BL/6mice [28]. Similarly, these findings
are consistent with studies by Seo et al., demonstrating
that subcutaneous implantation of B16F10 cells mixed in
Matrigel containing PAF augmented and ETOP suppressed
the growth of experimental melanoma in C57BL/6-WTmice
[34]. Notably, PAF blocked this ETOP-mediated attenuation
of melanoma tumor growth in mice implanted with Matrigel
mixed B16F10 cells containing PAF and ETOP [34]. These
effects were mediated via NF-𝜅B-dependent upregulation of
antiapoptotic Bcl-2 and Bcl-xL genes that resulted in an inhi-
bition of ETOP-induced caspases 3, 8, and 9 activities [34].
Although these studies did not directly address the effects
of systemic ETOP and PAF-R agonists in the modulation of
experimental melanoma, they did support our findings that
PAF-R agonists can attenuate ETOP chemotherapy effects
against murine melanoma [34].
Notably, most melanomas express the PAF-R [27] and
B16F10 cells do not [25]. Ectopic expression of the PAF-R
in B16F10 cells resulted in similar increase in tumor
xenografts by exogenous CPAF as in xenografts implanted
with PAF-R deficient vector control cells in PAF-R expressing
syngeneic mice [25]. This CPAF-mediated increase growth
of PAF-R expressing and deficient tumor xenografts was not
seen in PAF-R deficient mice, suggesting the role of host
PAF-R versus tumoral PAF-R in mediating PAF-R agonists-
induced increased tumor growth [25]. Nevertheless, PAF-R
expression inB16F10melanoma cells enhances chemotherapy
mediated PAF-R agonists production compared to PAF-R
deficient B16F10melanoma cells [29]. In a similar line, studies
by Onuchic et al. reported that in PAF-R expressing human
SKmel37 melanoma cells, cisplatin treatment resulted in
increased expression of the PAF-R and its accumulation [35].
Treatment with exogenous PAF protected SKmel37 cells from
cisplatin-induced cell death. Moreover, systemic treatments
with cisplatin or PAF-R antagonist,WEB2086, attenuated the
growth of SKmel37 tumor xenografts substantially in nude
mice and this effect was pronounced in a group of mice
treated with a combination of cisplatin and WEB2086 [35].
Our previous studies have shown that systemic CPAF not
only augments murine melanoma but also enhances murine
epithelial Lewis Lung carcinoma (LLC1) tumor growth in
C57BL/6 mice [26]. We next investigated if CPAF can affect
the growth of murine EL4 lymphoma tumors. To that end,
0.5× 106 EL4 cells were injected s.c. into the flanks of C57BL/6
mice followed by treatment with or without CPAF as per our
published reports [25, 26]. We demonstrate that CPAF did
not modulate the growth of EL4 tumors as no significant
difference in tumor volumes was noted between vehicle- and
CPAF-treated mice (Figure 2(a)). The exact reason for this
discrepancy is not clear at this time; however, we observed
that the basal growth rate of EL4 tumors was two times faster
than B16F10 tumors (Figure 2(b)) and thus CPAF has no
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additional tumor promoting effect. Of interest, this is likely
not due to tumoral PAF-R expression as B16F10, LLC1, and
EL4 tumor cells do not express PAF-R mRNA ([25, 26] and
data not shown).This study does indicate that PAF-R agonists
mediated effects are specific for certain tumor types.
4. Conclusions
Our current studies indicate that systemic ETOP chemo-
therapy against experimental melanoma is more effective
when given simultaneous to the tumor cell implantation
and chemotherapy-induced inhibition of tumor growth is
blocked by exogenous PAF-R agonist. PAF-R agonist medi-
ated effects are tumor specific as EL4 lymphoma tumors were
not modulated by systemic CPAF as seen in B16F10 and LLC1
tumors. As many cancer patients also can be exposed to
exogenous prooxidative stressors that are known to generate
PAF-R agonists [17, 21–24, 33], these findings could have
clinical implications in chemotherapy treatment failure.
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